This is a working overview of trans-3-hexenoyl, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-15. Anything still debated is marked as such rather than presented as settled.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
== Epidemiology == Myocardial infarction is a common presentation of coronary artery disease. The World Health Organization estimated in 2004, that 12.2% of worldwide deaths were from ischemic heart disease; with it being the leading cause of death in high- or middle-income countries and second only to lower respiratory infections in lower-income countries. Worldwide, more than 3 million people have STEMIs and 4 million have NSTEMIs a year. STEMIs occur about twice as often in men as women. Rates of death from ischemic heart disease (IHD) have slowed or declined in most high-income countries, although cardiovascular disease still accounted for one in three of all deaths in the US in 2008. For example, rates of death from cardiovascular disease have decreased almost a third between 2001 and 2011 in the United States. In contrast, IHD is becoming a more common cause of death in the developing world. For example, in India, IHD had become the leading cause of death by 2004, accounting for 1.46 million deaths (14% of total deaths) and deaths due to IHD were expected to double during 1985–2015. Globally, disability adjusted life years (DALYs) lost to ischemic heart disease are predicted to account for 5.5% of total DALYs in 2030, making it the second-most-important cause of disability (after unipolar depressive disorder), as well as the leading cause of death by this date.
== Paralogs == Escherichia coli (E. coli) expresses two different forms of shikimate dehydrogenase, AroE and YdiB. These two forms are paralogs of each other. The two forms of shikimate dehydrogenase have different primary sequences in different organisms but catalyze the same reactions. There is about 25% similarity between the sequences of AroE and YdiB, but their two structures have similar structures with similar folds. YdiB can utilize NAD or NADP as a cofactor and also reacts with quinic acid. They both have high affinity of their ligands as shown by their similar enzyme (Km) values. Both forms of the enzyme are independently regulated.
Indirectly, lightweight nanocomposites for automobiles and other means of transportation could save fuel and reduce materials used for production; nanotechnology-enabled fuel cells and light-emitting diodes (LEDs) could reduce pollution from energy generation and help conserve fossil fuels; self-cleaning nanoscale surface coatings could reduce or eliminate many cleaning chemicals used in regular maintenance routines; and enhanced battery life could lead to less material use and less waste. Green Nanotechnology takes a broad systems view of nanomaterials and products, ensuring that unforeseen consequences are minimized and that impacts are anticipated throughout the full life cycle.
11 February – Azhar Ali, Labour's candidate in the Rochdale by-election, apologises after a recording of him reportedly saying that Israel had "allowed" the deadly attack by Hamas gunmen on 7 October was obtained by The Mail on Sunday. Labour condemns his remarks but continues to offer its support to his candidacy. 12 February – Labour withdraws its support for Rochdale candidate Azhar Ali. Tracey Crouch, MP for Chatham and Aylesford, announces she is standing down from Parliament at the next general election. Prime Minister Rishi Sunak appears on an hour long GB News People's Forum, where a selected audience of undecided voters are invited to ask him questions. The programme is presented by Stephen Dixon. 13 February – Labour withdraws its support for Graham Jones, the former MP for Hyndburn, who was going to contest the seat at the next general election, after it emerges he attended a meeting at which Azhar Ali made comments about Israel. 14 February – Former Labour Party leader Neil Kinnock endorses Vaughan Gething to lead Welsh Labour as the next First Minister of Wales. Conservative MP Tobias Ellwood tells BBC Radio 4's PM programme that politicians cannot be viewed as "fair game" after a large-scale pro-Palestinian protest outside his family home. 15 February – By-elections take place in Wellingborough and Kingswood. Labour's Gen Kitchen takes Wellingborough, the Conservative Peter Bone's former seat, which he had held with a majority of more than 18,000.
Sources: en.wikipedia.org
The main advantage of 60Co is that it is a high-intensity gamma-ray emitter with a relatively long half-life (over 5 years) compared to similar gamma-ray sources. The β-radiation is low-energy and easily shielded; however, the gamma rays are highly penetrating. The physical properties of cobalt such as resistance to bulk oxidation and low solubility in water give some advantages in safety in the case of a containment breach over some other gamma sources such as caesium-137. The main uses for 60Co are:
SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney), unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium/glucose cotransporter 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes. As of 2014, several medications of this class had been approved or were under development. In studies on canagliflozin, a member of this class, the medication was found to enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure.
On 1 July 2009, the Hydropower Corps officially became part of China's emergency management system as a disaster relief agency. The 3rd Hyrdopower Detachment's Search and Rescue Company was established in August 2013 and was the elite unit of the Hydropower Corps dedicated to Urban Search and Rescue.
=== Early History (1819-1823) === Physician Daniel Drake founded the Medical College of Ohio, the precursor to the University of Cincinnati College of Medicine, in 1819. It was the first medical school west of the Allegheny Mountains. Originally located in a room above a drugstore, the college graduated its first class of 24 students in 1821.
Ingested proteins are usually broken up into single amino acids or dipeptides in the small intestine and then absorbed. They can then be joined to form new proteins. Intermediate products of glycolysis, the citric acid cycle, and the pentose phosphate pathway can be used to form all twenty amino acids, and most bacteria and plants possess all the necessary enzymes to synthesize them (see more in Amino acid synthesis). Humans and other mammals, however, can synthesize only half of them. They cannot synthesize isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, histidine, and valine. Because they must be ingested, these are the essential amino acids. Mammals do possess the enzymes to synthesize alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine, the nonessential amino acids. While they can synthesize arginine, they cannot produce it in sufficient amounts for young, growing animals, and so these are often considered essential amino acids as well. If the amino group is removed from an amino acid, it leaves behind a carbon skeleton called an α-keto acid. Enzymes called transaminases can easily transfer the amino group from one amino acid (making it an α-keto acid) to another α-keto acid (making it an amino acid). This is important in the biosynthesis of amino acids, as for many of the pathways, intermediates from other biochemical pathways are converted to the α-keto acid skeleton, and then an amino group is added, often via transamination.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.